Don't Let the HCT-CI Fool You: Similar Outcomes with Myeloablative CD34+ Selected Allo-HCT Compared to Unmodified RIC Allo-HCT in Patients with AML or MDS and High Comorbidity Scores.
Pennisi, Martina, Cho, Christina, Devlin, Sean M., Ruiz, Josel D., Maloy, Molly A., Tomas, Ana Alarcon, Castillo, Nerea, Lin, Richard J., Politikos, Ioannis, Sanchez-Escamilla, Miriam, Scordo, MichaelVolume:
26
Journal:
Biology of Blood and Marrow Transplantation
DOI:
10.1016/j.bbmt.2019.12.704
Date:
March, 2020
File:
PDF, 244 KB
2020
File converter
More search results
More benefits 
